The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
AbbVie, upon completing its $63-billion acquisition of Allergan, plans to create a new global business, Allergan Aesthetics, which will include Allergan’s Botox and related products. The new business will become effective upon the expected...
Biogen has agreed to acquire from Pfizer a clinical-stage small-molecule drug for treating neurological diseases in a deal worth up to $710 million ($75 million upfront and $635 million in potential milestones).
The drug, a central nervous system...
A roundup of developments and latest news from Germany (Bayer, WuXi Biologics), South Korea (Avacta, Daewoong), and US (Hikma, ANI Pharmaceuticals).
Germany
Bayer, WuXi Biologics in Acquisition Agreement for Bayer’s Drug-Product Mfg Plant
Bayer...
California’s Governor Gavin Newsom has proposed a new CalRx generic-drug program in his 2020–21 State Budget proposal that he submitted to California’s State Legislature, which would make California the first state to create its own generic-drug...
The European Medicines Agency (EMA) and its European and international partners have launched a pilot program to increase their cooperation in the inspection of manufacturers of sterile medicines for human use. This new initiative is built on...
Boehringer Ingelheim (BI) has acquired worldwide exclusive rights to the preclinical interleukin-11 (IL-11) platform of Enleofen Bio, a Singapore-based biopharmaceutical company, for developing therapies across a broad range of fibro-inflammatory...
Amag Pharmaceuticals, a pharmaceutical company specializing in women’s health, reports that its President and Chief Executive Officer (CEO), William Heiden, plans to step down. He will remain in his role as President and CEO until a successor is...
Eli Lilly and Company has agreed to acquire Dermira, a biopharmaceutical company that develops new therapies for chronic skin conditions, for approximately $1.1 billion.
Lilly says the acquisition will expand its immunology pipeline with the...
MorphoSys, a Martinsried, Germany-based biopharmaceutical company, and Incyte, a Wilmington, Delaware-based, global biopharmaceutical company, have entered into a collaboration and license agreement to further develop and commercialize MorphoSys’...
Takeda Pharmaceutical has received a Complete Response Letter from the US Food and Drug Administration (FDA) in response to the submission of its biologics license application (BLA) for the approval of an investigational subcutaneous formulation of...
Novartis and Amazon Web Services (AWS), an Amazon.com company, have formed a multi-year strategic collaboration for pharmaceutical manufacturing, supply chain, and delivery operations using AWS’s portfolio of cloud services. Novartis says that the...
Novartis has completed its $9.7-billion acquisition of the Medicines Company, a biopharmaceutical company focused on cardiovascular diseases, through its wholly-owned subsidiary, Medusa Merger Corporation. As a result of the merger, The Medicines...
Merck & Co. has formed an exclusive worldwide research collaboration and license agreement, worth up to $2.5 billion with Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, and Astex Pharmaceuticals (UK), a wholly owned subsidiary of Otsuka...
A roundup of developments and latest news from China (BI, BeiGene), India (Biocon), Japan (Towa Pharmaceutical, Esteve), Singapore (Tessa Therapeutics), UK (AstraZeneca), and US (Aurobindo, Bausch Health).
China
BI Manufactures BeiGene’s...
Bristol-Myers Squibb has completed its previously announced divestment of its oral solid, biologics, and sterile-product manufacturing and packaging facility in Anagni, Italy, to Catalent.
The Anagni facility manufactures and packages...
